|
JP2020100582A
|
|
Multiple sclerosis inhibitor
|
|
JP2020030108A
|
|
Method of collecting data for predicting clinical effectiveness of blood purification therapy
|
|
JP2019047952A
|
|
Clinical evaluation apparatus, clinical evaluation method, and clinical evaluation program
|
|
JP2018172327A
|
|
Therapeutic agent for autoantibody-dependent autoimmune diseases
|
|
JP2018011546A
|
|
Methods for producing skeletal muscle progenitor cells
|
|
JP2017214337A
|
|
Muscular dystrophy treating agents
|
|
JP2017213245A
|
|
Passive-type respiratory exercise training device
|
|
JP2017197443A
|
|
Composition for treating tdp-43 proteinopathy
|
|
JP2017131197A
|
|
Experimental animal head fixing device and experimental animal photographing head fixing device
|
|
JP2016202443A
|
|
Social ability test method and social ability test system
|
|
JP2016088896A
|
|
Muscle-cell damage inhibitor
|
|
JP2011244754A
|
|
Detection and treatment for congenital muscular dystrophy with mitochondrial disorder
|
